Medicofarma

What Medicofarma does

Medicofarma S.A. is a privately held Polish pharmaceutical contract manufacturer founded in 2004 and headquartered in Warsaw, with GMP-certified production operations at a plant in the Tarnobrzeska Special Economic Zone 'Wisłosan' in Radom. The company provides full-service B2B contract manufacturing and development of medicinal products (OTC and Rx), dietary supplements, medical devices (including in-vitro diagnostic kits), cosmetics, and supplementary animal fodder mixes, serving pharmaceutical, supplement, medtech, cosmetics and animal-nutrition companies in Poland and across 11 export markets in Europe, North America and Oceania. Its certified infrastructure (GMP, HACCP, ISO 13485, ALFA), in-house R&D laboratory operational since Q1 2019, microbiology and analytical laboratories with UHPLC-Q-TOF, ICP/MS, FTIR and GC-MS triple-quadrupole instrumentation, and extended authorisation for clinical-trial-grade testing together form the technical backbone of its CDMO offering.

Medicofarma monetises across four streams: project-based contract manufacturing fees (formulation, production, packaging, labelling, serialization), licensing of medicinal product dossiers to European marketing partners, own-brand dermo-cosmetic sales via the vitamanature.pl e-commerce storefront (based on an exclusive patent license on the 4-N-Furfurylocytozyna / 4NFC anti-aging molecule from the Institute of Bioorganic Chemistry of the Polish Academy of Sciences), and serialization services. Strategic R&D depth comes from a long-running partnership with the Polish Academy of Sciences dating to 2015, which has yielded first-in-Poland products such as the MediPAN-2G+ FAST COVID RT-PCR test and the MediPAN FAST COVID + FLU differential test, and from a related R&D entity, Medicofarma Biotech S.A., which is developing RNA-based oncology candidates and contributes to the NUTRITECH functional-food programme.

The go-to-market combines direct B2B sales for CDMO engagements, dossier licensing for European OTC categories (pain, cold & flu, anti-cough, cardiovascular), D2C e-commerce for the 4NFC cosmetics line, and consortium-based grant funding from EU structural funds (Operational Programme Intelligent Development 2014–2020) and the Polish National Centre for Research and Development (NCBR NUTRITECH programme). Total disclosed EU/NCBR co-financing across three major R&D projects amounts to approximately PLN 14.5M, and the company has not raised any disclosed venture capital or private equity.

Name

Medicofarma

Legal name

Medicofarma S.A.

Website

https://medicofarma.pl

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Medicofarma S.A. is a privately held Polish GMP-certified contract manufacturer of medicinal products, dietary supplements, medical devices, cosmetics and animal fodder mixes, serving pharmaceutical and consumer-health companies in Poland and 11 export markets, with in-house R&D and a sister biotech entity.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Anti-Counterfeit & Track-and-Trace Packaging (Serialization, Security Features) (IMALAIAJ)

Keywords

• Contract pharmaceutical manufacturing
• GMP-certified production services
• Dietary supplement manufacturing
• Medical device manufacturing
• Pharmaceutical R&D services

Headquarters

HQ city

Radom

HQ country

Poland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Contract manufacturing services: Core B2B revenue stream: full-service contract manufacturing of medicinal products (OTC and RX), dietary supplements, medical devices, cosmetics, and supplementary fodder mixes for pets/service animals. Services span formulation development, manufacturing, packaging, labeling, serialization, and market launch support. Pricing is project-based/quote-driven depending on batch size, product form, regulatory complexity, and additional services required. Customers include small, medium, and large pharmaceutical companies.
2. Licensing of medicinal product dossiers: Revenue from licensing out innovative medicinal product dossiers (especially OTC) to partners interested in marketing them on the European market. Includes dossiers with clear indications aligned with regulatory requirements and strategic concepts in categories such as pain, cold & flu, anti-cough, and cardiovascular. Medicofarma supports regulatory steps if required.
3. Own-brand dermo-cosmetic products (via vitamanature.pl): Sale of proprietary anti-aging dermo-cosmetic products containing the patented 4-N-Furfurylocytozyna (4NFC) molecule. Products distributed through the online storefront vitamanature.pl (consumer-facing e-commerce channel). Product line includes intensive regenerating-brightening gel, light moisturizing cream, anti-wrinkle serum (4-week treatment), moisturizing-regenerating serum, hydro-lipid serum, and revitalizing anti-wrinkle serum.
4. Serialization services: Serialization service for prescription medicinal products, offered both for products manufactured at Medicofarma's own facility and for customer-provided articles. Recurring service revenue component tied to contract manufacturing engagements.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Medicofarma S.A. is a Polish contract pharmaceutical manufacturer that produces medicinal products (RX and OTC), dietary supplements, medical devices, cosmetics, and supplementary animal fodder mixes under GMP, HACCP, ISO 13485, and ALFA certifications. It offers full-service B2B contract manufacturing from formulation and R&D through production, packaging, labeling, serialization, and market launch support, and also develops and produces its own IVD diagnostic test kits (MediPAN) and an own-brand anti-aging dermo-cosmetic line based on the patented 4-N-Furfurylocytozyna (4NFC) molecule.

Differentiator

Problem solved

Functional benefit

Brands

• Vitamanature: Distribution/retail brand associated with Medicofarma's anti-aging cosmetic line containing the patented 4-N-Furfurylcytosine (4NFC) molecule; products are sold via vitamanature.pl.

Products and services

• Contract Manufacturing of Medicinal Products Full-service contract manufacturing of medicinal products (RX and OTC) under GMP, including formulation development, production, quality control, packaging, labeling, serialization, and market launch support. Target customers are pharmaceutical companies needing flexible, certified manufacturing capacity.
• Contract Manufacturing of Dietary Supplements Contract development and manufacturing of dietary supplements in capsules, tablets, gels, creams, serums, sachets, sticks, and monodose formats under GMP and HACCP. Includes expert support from concept to finished product and regulatory notification assistance for clients entering the dietary supplement market.
• Contract Manufacturing of Medical Devices Contract manufacturing of medical devices including in-vitro diagnostic (IVD) kits and other medical devices in ISO 13485-certified facilities. Serves medical device and IVD developers requiring regulatory-grade production.
• Medicofarma R&D Center Services In-house R&D Center offering analytical method development, stability studies, transcriptome and metabolome analyses, and pre-formulation/formulation development services for pharmaceutical, biotech, dietary supplement, medical device, and cosmetics clients.
• Animal Fodder Mixes (Contract Manufacturing) Contract manufacturing of supplementary fodder mixes for companion and service animals, performed under ALFA quality certification approved by the Chief Veterinary Inspectorate.
• Serialization Services Serialization service for prescription (RX) medicinal products, offered both for products manufactured at Medicofarma's own facility and for customer-provided articles requiring serialization compliance.
• MediPAN-2G+ COVID (RT-PCR Test Kit) Multi-target RT-PCR genetic test for the detection of SARS-CoV-2, one of the first Polish-manufactured molecular COVID-19 diagnostics. Produced by Medicofarma in collaboration with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences (ICHB PAN).
• MediPAN-2G+ FAST COVID (RT-PCR Test Kit) Faster iteration of the MediPAN-2G+ SARS-CoV-2 RT-PCR kit, with reaction time of approximately 1 hour and sensitivity >99%. Detects all known SARS-CoV-2 variants including DELTA and OMICRON mutations. Received a positive opinion from the National Institute of Public Health – NIZP-PZH in Warsaw.
• MediPAN FAST COVID + FLU (Differential RT-PCR Test Kit) First Polish genetic test that simultaneously distinguishes SARS-CoV-2 from influenza A and B in a single well, with internal ACE2 human gene control. RT-PCR reaction time approximately 1 hour. Developed in cooperation with ICHB PAN and tested with Polpharma.
• MHH SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold) Colloidal-gold lateral-flow antigen rapid test cassette for professional in-vitro qualitative detection of SARS-CoV-2 nucleocapsid antigen in nasal swab specimens, complementing Medicofarma's PCR-based MediPAN portfolio.
• Intensive Regenerating-Brightening Anti-Aging Gel (4NFC line) Intensively regenerating and brightening anti-aging gel from the proprietary 4-N-Furfurylocytozyna (4NFC) dermo-cosmetic line, packaged in monodose/tube format. Distributed via vitamanature.pl.
• Light Moisturizing Anti-Aging Cream (4NFC line) Light moisturizing anti-aging cream from the proprietary 4-N-Furfurylocytozyna (4NFC) dermo-cosmetic line. Distributed via vitamanature.pl.
• Anti-Wrinkle 4-Week Treatment Serum (4NFC line) Anti-wrinkle serum in a 4-week treatment course, part of the proprietary 4-N-Furfurylocytozyna (4NFC) dermo-cosmetic line. Distributed via vitamanature.pl.
• Licensing of Medicinal Product Dossiers (OTC) Licensing out of innovative medicinal product dossiers, especially OTC, in categories such as pain, cold & flu, anti-cough, and cardiovascular, to partners interested in marketing them on the European market. Includes regulatory support from Medicofarma.

Quantifiable outcome

• RT-PCR reaction time of approximately 1 hour for MediPAN-2G+ FAST COVID test (vs. longer standard tests)
• +6 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core, minor and flagship.

• University of Life Sciences in Poznań (Uniwersytet Przyrodniczy w Poznaniu)coreStrategic or Co-development Partner · 20 October 2023Consortium partner in the NUTRITECH programme project (NCBR-funded, signed 20.10.2023, total PLN 8,600,221.34, co-financing PLN 5,306,698.36). Project: 'Vitamin drink enriched with naturally derived compounds with scientifically proven effectiveness to support the treatment of irritable bowel syndrome.' Joint effort with Medicofarma S.A. and Medicofarma Biotech S.A.
• Medicofarma Biotech S.A.coreStrategic or Co-development Partner · 20 October 2023Sister/affiliated R&D company and consortium partner in the NUTRITECH programme project (NCBR-funded, signed 20.10.2023). Joint development of functional food innovation for IBS support. Medicofarma Biotech also operates two state-of-the-art research centres (one GLP-certified) with 20 scientists (50% PhDs) focused on RNA-based anti-cancer therapies (glioblastoma, ovarian, hepatic, breast cancer) and gastrointestinal/oral disease treatments. Member of the European Federation of Biotechnology since early 2023.
• PolpharmaminorStrategic or Co-development Partner · 1 January 2021Referenced in media coverage as a collaboration partner for the first Polish genetic COVID-19 test (MediPAN-2G+ FAST COVID) and the differential COVID/Flu test (MediPAN FAST COVID + FLU). Co-developed alongside Medicofarma S.A. and ICHB PAN; Polpharma participated in development and rollout.
• Polish Academy of Sciences (Polska Akademia Nauk, PAN) in Poznań – Institute of Bioorganic Chemistry (ICHB PAN) and Institute of EpigeneticsflagshipStrategic or Co-development Partner · 1 January 2015Long-term R&D partnership running since 2015. Jointly developed the R&D Laboratory (operational since 2019). Acquired patent license on 4-N-Furfurylocytozyna (4NFC) anti-aging molecule. Co-developed the first Polish genetic test for SARS-CoV-2 (MediPAN-2G+ FAST COVID) and the first Polish differential COVID/Flu test (MediPAN FAST COVID + FLU). The PAS Institute of Epigenetics in Poznań carried out research on 'Epigenetics as a modern tool for studying the health benefits of dietary supplements and foods for special medical purposes.'
• Vitamanature.plcoreChannel Partner/ Reseller/ DistributorOnline storefront that distributes Medicofarma's proprietary anti-aging dermo-cosmetic product line based on the patented 4-N-Furfurylocytozyna (4NFC) molecule. Sells the intensive regenerating-brightening gel, light moisturizing cream, anti-wrinkle 4-week serum, moisturizing-regenerating serum, hydro-lipid serum, and revitalizing anti-wrinkle serum. Linked from Medicofarma's website as the consumer purchase channel.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Fareva: French-headquartered European CDMO serving pharmaceuticals, cosmetics, and medical devices. Comparable in multi-segment contract manufacturing (drugs + cosmetics + devices) and certification-driven customer targeting, but at significantly larger group scale.
• Teva Pharmaceutical Industries: Global generics giant with substantial European manufacturing footprint (including Poland via Teva Operations Poland). Operates as a broad incumbent in the same finished dosage form manufacturing space Medicofarma serves, competing for contract and supply contracts but at vastly larger scale.
• Aenova Group: One of Europe's largest contract manufacturers, offering solid, semi-solid, liquid, and sterile dosage form production across pharma and dietary supplements. Competes with Medicofarma for European CDMO outsourcing contracts at a substantially larger scale and broader geographic footprint.
• Catalent: Global CDMO (now under Novo Holdings) offering pharmaceutical and biologics contract manufacturing, including softgel, oral, sterile, and analytical services. Represents the upper-bound incumbent Medicofarma would compete against for mid-to-large pharma outsourcing decisions.

Direct peers

• Aflofarm: Polish pharmaceutical and dietary supplement manufacturer with a broad OTC and consumer health portfolio. Comparable to Medicofarma in supplement/OTC manufacturing scale, GMP-certified production, and Polish-market brand presence.
• Adamed Pharma: Polish pharmaceutical group with significant own-brand and contract manufacturing operations across RX, OTC, dietary supplements, and medical devices. Directly competes with Medicofarma for Polish and Central European CDMO contracts and shares a similar customer mix of mid-market pharma and supplement brands.
• Hasco-Lek: Polish pharmaceutical manufacturer producing generics, OTC drugs, dietary supplements, cosmetics, and medical devices under GMP/HACCP/ISO 13485 conditions. Directly comparable in product portfolio breadth, certification stack, and customer segments to Medicofarma.
• Biofarm: Polish pharmaceutical manufacturer specializing in finished dosage forms (tablets, capsules, liquids, ointments) and dietary supplements. Comparable CDMO/CMO offering and customer base to Medicofarma, with a similar focus on small-to-mid-batch contract manufacturing.
• Polpharma: Poland's largest pharmaceutical manufacturer and a direct contract manufacturing / co-development peer. Polpharma collaborated with Medicofarma and ICHB PAN on the MediPan COVID/Flu diagnostic tests and competes for the same Polish and European CDMO outsourcing mandates across RX/OTC drugs, supplements, and medical devices.

Emerging players

• Mabion: Polish biotech and contract development manufacturer specializing in biologics and biosimilars. Comparable as a Polish-headquartered life sciences CDMO with R&D capabilities, though focused on biologics rather than small molecules; represents an adjacent emerging CDMO peer in the Polish market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medicofarma-s-a-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicofarma